ANTCF (Aion Therapeutic) Equity-to-Asset: -3.87 (As of Jan. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aion Therapeutic Equity-to-Asset?

Aion Therapeutic ANTCF Equity-to-Asset is -3.87 as of Jan. 2025.

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Aion Therapeutic's Total Stockholders Equity for the quarter that ended in Jan. 2025 was $-3.23 Mil. Aion Therapeutic's Total Assets for the quarter that ended in Jan. 2025 was $0.83 Mil. Therefore, Aion Therapeutic's Equity to Asset Ratio for the quarter that ended in Jan. 2025 was -3.87.

The historical rank and industry rank for Aion Therapeutic's Equity-to-Asset or its related term are showing as below:

ANTCF's Equity-to-Asset is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.6
* Ranked among companies with meaningful Equity-to-Asset only.

Aion Therapeutic  (OTCPK:ANTCF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Aion Therapeutic Equity-to-Asset Related Terms

Aion Therapeutic Equity-to-Asset Historical Data

* Premium members only.

The historical data trend for Aion Therapeutic's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aion Therapeutic Equity-to-Asset Chart

Aion Therapeutic Annual Data
Trend Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Equity-to-Asset
Get a 7-Day Free Trial 0.64 0.25 -16.03 -12.94 -5.51

Aion Therapeutic Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 -5.51 -3.33 -2.66 -3.87

ANTCF vs CBDY, GRPS, PLSH: Equity-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aion Therapeutic's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aion Therapeutic Equity-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aion Therapeutic's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Aion Therapeutic's Equity-to-Asset falls into.


Aion Therapeutic Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Aion Therapeutic's Equity to Asset Ratio for the fiscal year that ended in Apr. 2024 is calculated as

Equity to Asset (A: Apr. 2024 )=Total Stockholders Equity/Total Assets
=-2.8182472613458/0.51159951959821
=-5.51

Aion Therapeutic's Equity to Asset Ratio for the quarter that ended in Jan. 2025 is calculated as

Equity to Asset (Q: Jan. 2025 )=Total Stockholders Equity/Total Assets
=-3.2264360435008/0.83299154151562
=-3.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Equity-to-Asset →
What does a Equity-to-Asset of -3.87 mean?
Aion Therapeutic (ANTCF) has a Equity-to-Asset of -3.87 as of Jan. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aion Therapeutic and its competitors.
Is Aion Therapeutic's Equity-to-Asset too high?
Aion Therapeutic's current Equity-to-Asset is -3.87.
How does Aion Therapeutic's Equity-to-Asset compare to CBDY and GRPS?
Aion Therapeutic's Equity-to-Asset of -3.87 can be compared against companies in the Drug Manufacturers industry. The industry median Equity-to-Asset is 0.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Aion Therapeutic and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aion Therapeutic's current Equity-to-Asset is -3.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aion Therapeutic stock overvalued right now?
Aion Therapeutic (ANTCF) has a current Equity-to-Asset of -3.87. The current Equity-to-Asset is -3.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Aion Therapeutic (ANTCF), the current Equity-to-Asset is -3.87 as of Jan. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aion Therapeutic Business Description

Address 700 West Georgia Street, Suite 2200, Vancouver, BC, CAN, V7Y 1K8
Aion Therapeutic Inc is in the business of research and development, treatment, data mining, and state of the art artificial intelligence techniques, focused on the development of combinatorial pharmaceuticals, nutraceuticals, and cosmeceuticals utilizing compounds from cannabis, psychedelic mushrooms, fungi, natural psychedelic formulations, and other medicinal plants in a legal environment for this type of discovery. During the year ended the Company had one operating segment, being health and wellness, dedicated to delivering state-of-the-art water filtration solutions. Geographically company earns revenue from USA.